|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||84.45 - 85.38|
|52 Week Range||72.67 - 94.19|
|PE Ratio (TTM)||26.26|
|Forward Dividend & Yield||2.72 (3.19%)|
|1y Target Est||98.06|
What Should Vanda Pharmaceuticals Investors Be Watching in 2018? Investors can expect a slew of critical developments from Vanda Pharmaceuticals (VNDA) in 2018. It expects to begin a tradipitant Phase 3 study in the first half of 2018 for atopic dermatitis and publish results from the tradipitant clinical study for the treatment of gastroparesis by the end of fiscal 2018.
Greece’s parliament will investigate whether senior political leaders took bribes from Swiss pharmaceutical giant Novartis to fix drug prices and boost its sales to public hospitals.
Greece’s parliament has voted to investigate allegations that 10 senior politicians, including two former prime ministers, the country’s EU commissioner and the governor of the central bank, accepted bribes ...
Novartis’s (NVS) Gilenya reported sales of $825 .0 million in 4Q17, which is a year-over-year (or YoY) drop of 1.0% on a constant currency basis. The court declared that Gilenya’s formulation patent protecting the drug until 2026 is invalid.
Novartis: What Are the Major Growth Drivers for 2018? Aimovig, which is Novartis’s (NVS) investigational migraine prophylaxis therapy, is currently under review by the FDA and the European Medicines Agency (or EMA). More than 10.0% of the adults in the world suffer from migraine.
Vasant Narasimhan, the 41-year-old chief executive at Novartis AG, is vowing data science and digital technologies will revolutionize the company’s drug-development pipeline.
Greek lawmakers begin discussions Wednesday on the alleged role of former senior government officials in a Novartis AG bribery case, which is part of a drug-overpricing scandal that’s estimated to have ...
Clinical stage biopharma company resTORbio, Inc. (NASDAQ: TORC )'s TORC1 inhibition program uses a protein called serine/threonine kinase that aims to regulate aging and aging-related diseases conditions ...
Novartis: What Are the Major Growth Drivers for 2018? On October 30, 2017, Novartis (NVS) announced its plans to acquire radiopharmaceutical company Advanced Accelerator Applications. On January 22, 2018, Novartis completed the tender offer.
Novartis: What Are the Major Growth Drivers for 2018? Novartis’s (NVS) Promacta reported sales if $255 million in 4Q17, which is a year-over-year (or YoY) rise of 43.0% on a constant currency basis. On January 4, 2018, Novartis announced that the FDA granted breakthrough therapy designation to the combination of Promacta and immunosuppressive therapy.
Novartis (NVS) announces positive results from the phase III study on multi-blockbuster drug Cosentyx for the treatment of moderate-to-severe scalp psoriasis.
NEW YORK, NY / ACCESSWIRE / February 20, 2018 / U.S. markets closed Friday with weekly gains in the range of 4 percent to 5 percent. The Dow Jones Industrial Average gained 0.08 percent to close at 25,219.38, ...
The Greek parliament voted on Thursday to investigate politicians, including former prime ministers, over allegations of bribery from the Swiss drugmaker Novartis. Kate King reports.